BMRN: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Total revenues	2,346,688	-	-	-
Cost of sales	441,733	-	-	-
R&d expenses-Research And Early Pipeline	280,158	-	-	-
R&d expenses-Later Stage Clinical Programs	279,074	-	-	-
R&d expenses-Marketed Products	170,285	-	-	-
S&m expenses	355,958	-	-	-
G&a expenses	350,852	-	-	-
Other segment expense (income), net	73,154	-	-	-
Net income	395,474	426,218	185,686	301,916
Depreciation and amortization	59,119	40,632	22,069	72,819
Non-cash interest expense	1,969	1,320	660	2,699
Accretion of discount on investments	3,695	2,717	1,362	6,619
Stock-based compensation	134,496	85,231	37,700	149,652
Gain on sale of nonfinancial assets	0	0	0	10,000
Impairment of assets and other noncash adjustments	2,967	2,967	2,967	-
Acquired in-process research & development expense	220,963	-	-	-
Deferred income taxes	48,125	61,771	28,429	13,709
Unrealized foreign exchange gain	-244	5,306	10,026	22,352
Other	1,704	1,916	1,267	1,254
Accounts receivable, net	107,378	156,124	57,590	130,456
Inventory	98,796	72,462	24,335	29,259
Other current assets	32,125	15,092	6,327	19,939
Other assets	32,679	13,505	1,624	31,839
Accounts payable and accrued liabilities	119,478	3,111	-2,655	68,019
Impairment of assets and other non-cash adjustments	-	-	-	19,889
Other long-term liabilities	21,892	5,537	2,069	10,229
Net cash provided by operating activities	728,350	359,665	174,394	387,214
Purchases of property, plant and equipment	62,316	33,869	16,768	65,894
Maturities and sales of investments	294,547	195,738	77,804	478,436
Purchases of investments	313,262	202,433	89,274	352,371
Proceeds from sale of nonfinancial assets	0	0	0	10,000
Purchase of intangible assets	5,569	266	0	11,225
Acquisition, net of cash acquired	285,193	-	-	-
Other	0	-	-	-1,141
Net cash provided by (used in) investing activities	-371,793	-40,830	-28,238	60,087
Proceeds from exercises of awards under equity incentive plans	7,714	7,707	0	41,415
Taxes paid related to net share settlement of equity awards	53,265	51,089	38,779	72,651
Repayments of convertible debt	0	-	-	494,987
Payments of contingent consideration	-	-	-	0
Other	0	0	0	-3,083
Net cash used in financing activities	-45,551	-43,382	-38,779	-529,306
Effect of exchange rate changes on cash	-3,740	-4,479	-1,416	2,326
Net increase (decrease) in cash and cash equivalents	307,266	270,974	105,961	-79,679
Cash and cash equivalents at beginning of period	942,842	-	-	-
Cash and cash equivalents at end of period	1,250,108	-	-	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

BMRN: the cashflow